News

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels.

Press Releases

BIO Statement Re Updated GREET Model to Measure…

The following statement may be attributed to Beth Ellikidis, BIO's Vice President for Agriculture & Environment: “Today’s release of an updated methodology to qualify crop-based sustainable aviation fuel (SAF) for federal tax credits is a…

Learn more

Admiral William McRaven to Keynote 2024 BIO…

Retired U.S. Navy (SEAL) Four-Star Admiral and the Former Chancellor of The University of Texas System, William McRaven, to Discuss Leadership, Global Events, and the National Security Importance of Biotechnology with BIO CEO, John Crowley …

Learn more

BIO Reiterates Lack of Basis for Mexico’s Ban on…

Seed technology companies comply with Mexico’s biosafety regulations, and Mexico should do the same, BIO said today in its response to the panel set up to determine if Mexico’s ban on imports of genetically modified corn violate its commitments…

Learn more

Letters, Testimony, & Comments

Browse All

BIO Comments to HHS's Centers for Medicare &…

The Biotechnology Innovation Organization appreciates the opportunity to comment on the Center for Medicare and Medicaid Services’ Information Collection Request on the Part C and Part D Medicare Prescription Payment Plan Model Documents.

Learn more

BIO Comments to the Department of Justice on…

In response to their advance notice of proposed rulemaking (ANPRM), BIO submitted comments to the DOJ's National Security Division on implementing the White House Executive Order of February 28, 2024, “Preventing Access to Americans’ Bulk Sensitive…

Learn more

Biotech Companies Express Concern With Proposed…

We, the undersigned, are writing to express our strong concern with a proposed update to the Medicaid Drug Rebate Program. If finalized in its current form, the proposed rule (CMS-2434-P) would impose significant costs to the government and industry…

Learn more

Amicus Briefs

Browse All

BIO FILES AMICUS BRIEF CHALLENGING FTC’S…

The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge the Federal Trade Commission (FTC) lawsuit to block the acquisition of Horizon by Amgen. The amicus brief was filed in the U.S. District Court, Northern…

Learn more

BIO Files Amicus Brief in U.S. ex rel. Scutte v…

BIO has filed an amicus brief in U.S. ex rel. Scutte v. SuperValu Inc., which addresses the issue of the intent requirement under the False Claims Act (FCA). Specifically, BIO urges the Court to uphold the view that a firm does not…

Learn more

BIO JOINS AMICUS BRIEF CHALLENGING COURT’S…

The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge a District Court’s unprecedented ruling (related to a single drug known as mifepristone) that would create regulatory barriers and potentially upend FDA’s…

Learn more